New Knee Osteoarthritis Drug Trial Underway
A Phase 2b trial of the immunotherapy Allocetra is now testing a potential new treatment for moderate-to-severe joint pain.
Updated on Oct. 28, 2026 in Arthritis
Live Poll
Do you believe current medical research is sufficiently prioritizing treatments for aging-related chronic conditions?
Enlivex has randomized 135 participants into a Phase 2b clinical trial evaluating the immunotherapy drug Allocetra for knee osteoarthritis. The study is enrolling adults aged 64 and older across sites in the United States, Denmark, and Poland.
Why it matters
As knee osteoarthritis affects 32 million Americans and is projected to impact 78 million by 2040, researchers are testing new immunotherapies to address the condition. This trial aims to determine if Allocetra can offer a new treatment path for those with moderate-to-severe symptoms.
This Phase 2b multicenter, double-blind, placebo-controlled trial has randomized 135 patients aged 64 and older out of a planned enrollment of 182. Final efficacy and safety results for the immunotherapy remain under investigation, with topline six-month data expected in mid-2027.
The players
Enlivex
A clinical-stage immunotherapy company based in Nes-Ziona, Israel, focused on developing treatments for inflammatory conditions.
FDA
The United States agency responsible for regulating pharmaceuticals and granting special designations for therapies addressing serious conditions.
The details
Allocetra is an experimental immunotherapy designed to address age-related primary knee osteoarthritis. The trial utilizes a double-blind, placebo-controlled design to evaluate the drug's impact on moderate-to-severe joint inflammation and pain. Participants received their first injection during the randomization process to begin the testing period.
Timeline
July 2026: The FDA granted RMAT designation to Allocetra.
October 28, 2026: Enlivex announced the randomization of 135 patients.
Mid-2027: Expected reporting of topline six-month data.
2040: Projected impact of knee osteoarthritis on 78 million Americans.
Health Landscape
The use of the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation reflects a broader regulatory trend of prioritizing the development of novel immunotherapies for chronic joint diseases. This approach marks a shift toward addressing inflammation directly in moderate-to-severe osteoarthritis cases.
For adults managing moderate-to-severe knee osteoarthritis, this trial highlights an ongoing shift toward immunotherapy research for joint health. If you are experiencing persistent joint pain, it is worth discussing the latest standard treatment options and emerging research with your physician.
The takeaway
While clinical trials for new therapies are promising, they are not immediate treatment options for current patients. Readers should continue to follow established clinical guidelines for osteoarthritis management and consult their healthcare provider about any changes in their symptoms.
What happens next
Enlivex expects to release topline six-month data from the Phase 2b trial in mid-2027.
Further reading
Learn more about the latest research and standard care options in the Arthritis section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe current medical research is sufficiently prioritizing treatments for aging-related chronic conditions?
